Excretion of hydroxyurea into milk.

The authors conducted a literature review focusing on hydroxyurea excretion into breast milk. They analyzed existing studies that measured drug concentrations in maternal milk samples. The review approach included examining case reports and pharmacokinetic data. The authors compared findings with those of other antineoplastic agents. No new experiments were performed; all conclusions are based on prior research. The synthesis of evidence involved evaluating the consistency of results across studies. The literature review approach prioritized human studies over animal models. The findings were contextualized within broader discussions of drug safety in lactation.

Hydroxyurea was detected in breast milk samples from treated patients. The concentration levels suggest potential exposure to the nursing infant. The study found no prior evidence of hydroxyurea being completely absent in breast milk. Other antineoplastic agents showed variable excretion patterns in milk. The data suggest that hydroxyurea transfer into milk is not negligible. The authors propose that this finding should inform clinical recommendations. The review highlights the need for caution in recommending lactation during hydroxyurea therapy. These results suggest a need for further pharmacokinetic studies in this population.

The authors conclude that hydroxyurea is excreted into human breast milk. This finding suggests a potential risk for infant exposure through lactation. The review does not propose definitive safety thresholds for this drug in breastfeeding. The authors suggest that these findings should guide clinical decision-making. The synthesis of evidence does not resolve whether the drug is entirely safe for lactation. The study does not assign essentiality to any specific drug monitoring strategy. The authors suggest that further research is needed to quantify infant exposure risks. These conclusions are based solely on the available literature and do not propose new therapeutic directions.